Florence Salmon

VP Regulatory Affairs at HOOKIPA Pharma Inc.

Speaker

Florence gained considerable experience in cell and gene therapies development and regulatory affairs in the past 20 years, bringing many of the early cell and gene therapies to the clinic and to marketing authorisation. She worked, among other companies, on the approval of Glybera (first gene therapy) and supported the development of several AAV-based gene therapies for various disease areas. At Novartis she worked on the global approval of Kymriah (first CAR-T product), Luxturna and Zolgensma, and on the development pipeline. After participating in the building of several Cell and Gene start-ups, she now works as Vice President Regulatory Affairs at Hookipa Pharma.